VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Turaga Discusses Current Surgical Setting of Sarcoma

Kiran Turaga, MD, MPH
Published: Monday, May 08, 2017



Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses the current surgical setting of sarcoma.

Although surgical resection remains standard for patients with retroperitoneal sarcomas, Turaga says, the concept of compartmental resection is being explored once again.

Recently, adjuvant systemic chemotherapy was explored in patients with sarcomas, but the data was not strong for sarcomas as a group, says Turaga. There does seem to be benefits in some subgroups, such as leiomyosarcoma.

Additionally, the recent investigation into the use of multi-receptor TKIs, such as pazopanib (Votrient), is interesting, Turaga says.
 


Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses the current surgical setting of sarcoma.

Although surgical resection remains standard for patients with retroperitoneal sarcomas, Turaga says, the concept of compartmental resection is being explored once again.

Recently, adjuvant systemic chemotherapy was explored in patients with sarcomas, but the data was not strong for sarcomas as a group, says Turaga. There does seem to be benefits in some subgroups, such as leiomyosarcoma.

Additionally, the recent investigation into the use of multi-receptor TKIs, such as pazopanib (Votrient), is interesting, Turaga says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x